Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
This funding opportunity aims to support research on how incretin mimetics, a type of drug that affects hormones like GLP-1 and GIP-1, influence cancer risk. It seeks to fund both preclinical and patient-based studies. The goal is to draw skilled scientists to explore the mechanisms by which these drugs affect cancer risk, moving beyond their short-term effects like weight loss and diabetes ma…
The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientist…
Funding Source
Awards & funding
Dates
Supporting links
Secure Grant Funding 10x Faster
Scout delivers AI-powered grant writing paired with experts that's faster, more affordable, and built to win.
Already have an account? Sign In
Trusted by 500+ Happy Customers